ABSTRACT
INTRODUCTION
Fetal medicine has experienced significant developments in the last two decades, especially regarding fetal therapy. Fetal surgery represents a promising approach for several fetal diseases, particularly for the treatment of twin-to-twin transfusion syndrome (TTTS) 1, 2 . Although fetoscopy is associated with an increased survival rate, it is also considered invasive and responsible for fetal and maternal complications that can affect neonatal outcome 3, 4 . These complications are partly associated with the opening of the amniotic cavity. In the context of TTTS, a non-invasive treatment that could occlude deep anastomoses would avoid the risks of invasive fetoscopy while offering an effective therapy.
The efficacy of high-intensity focused ultrasound (HIFU) has been proven clinically for non-invasive tissue ablation when applied to the brain, uterine fibroids, bones and liver [5] [6] [7] [8] . Ultrasound waves are commonly generated by a spherical piezoelectric transducer and directed harmlessly across the skin and intervening tissue. Only at the focus of the transducer can a combination of thermal and mechanical effects produce highly localized tissue destruction 9 . The shape of the lesion following a single HIFU exposure will vary according to the transducer characteristics, but it is typically ellipsoidal. Diagnostic imaging could be performed to identify target tissue and monitor tissue responses, supporting HIFU as a possible option for non-invasive fetal therapy. We have previously developed a toroidal HIFU transducer that enables the destruction of large areas of tissue 10 . In a recent study, we demonstrated the ability of this toroidal transducer to induce lesions in the human placenta, in an ex-vivo model, without damaging intervening tissue 11 . However, testing the fetal-maternal safety of ultrasound-guided HIFU to create placental lesions in an animal model of pregnancy is an essential preliminary step before commencing human clinical trials. While no model can truly represent twin placentation, the pregnant monkey provides a good substitute. The pregnant monkey is an ideal animal to study the different treatment options available for placental abnormalities owing to its similar anatomy and physiology to those of humans.
Here, we report a feasibility study using a monkey model of pregnancy. The objectives of this study were: (1) to evaluate the feasibility and reproducibility of creating HIFU lesions in the placenta of pregnant monkeys in vivo; (2) to examine the lesions produced using ultrasound, gross pathology and microscopy; and (3) to evaluate local and general tolerance to the treatment.
SUBJECTS AND METHODS

HIFU equipment
A toroidal ultrasound transducer (Imasonic, Voraysur-l'Ognon, France) with a radius of curvature of 70 mm and a diameter of 67 mm was used. The operating frequency was 2.5 MHz. The transducer was divided into 32 independent concentric rings of equal surface area (78 mm 2 ). Unlike the focus of a spherical transducer which is ellipsoidal in shape, a toroidal transducer creates two focal zones, the principal one being ring shaped and located at the radius of curvature of the transducer. Because of the geometric characteristics of a torus, the ultrasound beams intersect between the principal focal ring and the transducer surface to form a secondary focal zone. This secondary focal zone reinforces the homogeneity of the lesion. The toroidal geometry used in this study has been shown previously to be appropriate for intraoperative use 12 . The focal zones are positioned precisely to ablate tissue between the surface and a predetermined depth, as defined by preliminary numerical simulations. A 7.5-MHz (bandwidth, 55%) phased-array ultrasound imaging probe (Vermon, Tours, France) was placed in the center of the therapy transducer and connected to a BK HAWK 2102 EXL ultrasound system (BK Medical, Herlev, Denmark) to guide treatment. The ultrasound imaging plane was aligned with the HIFU acoustic axis. In this study, the imaging probe was used to identify the treatment area before HIFU and to visualize the lesions after it. The transducer was guided by a system described elsewhere 13 . A polyurethane envelope containing a degassed liquid (Ablasonic ® , Edap TMS, Vaulx-en-Velin, France) was used to cool the transducer and provide acoustic coupling with the surface of the organ.
Animals
Trials were conducted on eight pregnant cynomolgus monkeys (Macaca fascicularis) at an average gestational age of 72 ± 4 days. The normal duration of gestation in the cynomolgus monkey is approximately 180 days. In our experience, a placenta bipartita is present in 75% of cases and this is the principal structural difference from the human placenta.
All experiments were carried out in compliance with national and European legislation, as well as with institutional guidelines concerning animal experimentation. Surgical procedures were carried out in accordance with European requirement 2010/63/UE. The protocol was reviewed and approved by the Animal Care and Use Committee CELYNE (C2EA #42).
HIFU procedure
Following premedication with atropine (1.25 mg i.m.) and dexamethasone (4 mg i.m.), pregnant monkeys were prepared for treatment under ketamine hydrochloride (20 mg/kg i.m.) and chlorpromazine (2 mg/kg i.m.). After intubation, anesthesia was continued with isoflurane in a 70:30 N 2 O/O 2 mixture. Heart rate was monitored and artificial respiration was adjusted to maintain end-tidal CO 2 at 4.5-6%. Rectal temperature was monitored continuously throughout the procedure. Fetal heart rate was recorded using a 2-MHz Sonicaid Doppler machine (Huntleigh Technologies, Cardiff, UK). Values were recorded before, during and after HIFU exposure. The animals were placed in a dorsal decubitus position and the skin was shaved at the location of the treatment. A short skin incision was made after skin asepsis to insert two thin (0.33-mm diameter) thermocouples (MT-29, Physitemp, Clifton, NJ, USA) to measure the subcutaneous and intra-amniotic temperatures. The thermocouples were placed within the HIFU beam under ultrasound guidance. Several HIFU exposures were performed and the subcutaneous sensor was repositioned after each exposure. The positioning of the HIFU device and the surgical procedure performed after exposure are shown in Figure 1 . Ultrasound images were acquired to determine the region in the placenta to be treated and to measure the thickness of the abdominal wall, myometrium and placenta. These preliminary images were acquired with a 12-MHz imaging probe (BK Medical) for high resolution. The HIFU device was then placed on the skin of the animal ( Figure 1 ) and the targeted region in the placenta was visualized using the ultrasound imaging probe integrated within the HIFU device. The focus of the transducer was placed at the placenta by adjusting electronically the depth of focus and by changing the quantity of water in the envelope covering the transducer, according to the thickness of different tissues (skin, muscle, fat and myometrium) between the transducer and the placenta. Single HIFU lesions were created after confirmation of adequate placement of the focus at the targeted placental area. In a preliminary in-vitro study, we determined that a free-field acoustic power of 90 W applied for 55 s was necessary for ablating human placental tissue 11 . For in-vivo application in the pregnant monkey model, we decided, after additional numerical simulations, to start the experiments with a lower acoustic power and shorter exposure time, and to gradually increase them. The parameters that were used in this study were acoustic powers of 65, 80, 110 and 120 W applied for 30, 15 and 20 s. This gradual increase in the total energy delivered was chosen to determine the best compromise for creating a large HIFU lesion without damaging overlying tissues. Between one and three HIFU lesions were created in each animal with the aim of macroscopically and microscopically describing clearly their characteristics.
Ultrasound images of the placenta were acquired immediately after HIFU treatment and the dimensions and characteristics of the HIFU lesions were compared with the gross pathology.
Surgical procedure
A midline abdominal incision was performed for uterotomy and the fetus and placenta were carefully extracted. After uterotomy closure, an abdominal inspection was undertaken to identify potential lesions in the maternal tissue, mainly the abdominal cavity. A macroscopic examination of the fetus was performed to verify potential fetal complications. The aponeurosis and skin were closed using Vicryl 2.0. The animals received postoperative analgesic medication (ketoprofen 2 mg/kg and buprenorphine 0.01 mg/kg). Placentae were fixed in 5% formaldehyde for 2 days, and hematoxylineosin-saffron-stained slides were prepared for histological examination. In the presence of fetal damage, microscopic examination of the fetal tissue was performed.
RESULTS
Mean gestational age of the animals was 72 ± 4 days ( Table 1 ). In total, 13 HIFU exposures were performed and six placental lesions were observed. The first placental lesion was created using an acoustic power of 80 W applied for 30 s. The diameters of this lesion were 10.2 mm and 9.8 mm and its depth was 5.6 mm, corresponding to the thickness of the placenta macroscopically. The thickness of the tissue (skin, fat, muscle and myometrium) between the transducer and the placenta was 13.5 mm.
There was no secondary lesion in the intervening tissue. These parameters were tested twice, but only one lesion was created, indicating that no reproducible ablation could be achieved under these exposure conditions. The energy delivered to the tissues was increased to an acoustic power of 120 W and an exposure time of 20 s, and a total of five lesions at different locations in two cases were created. Under these exposure conditions, the average diameters of the lesions were 6.4 ± 0.5 mm and 7.8 ± 0.7 mm macroscopically ( Table 2 ). On average, the depth of the lesions was 3.8 ± 1.5 mm for an average placental thickness of 6.7 ± 1.1 mm. These lesions were created in the deepest part of the placenta, where arteriovenous anastomoses typically lie. The lesions appeared macroscopically as white in color with well-defined hemorrhagic margins (Figure 2) . No lesion was created using other exposure parameters.
For all experiments, there was no significant change in fetal or maternal parameters during or after HIFU exposure (Table 1) . During Cesarean section, a maternal lesion was observed in one monkey (Case 6). This lesion was a uterine burn of 12.7 × 9.7 mm, associated with a fetal skin burn of 15.0 × 6.0 mm. These two secondary lesions were created with an acoustic power of 120 W applied for 20 s but repeated three times at the same location. Occurrence of this complication only after three repeat exposures at the same location suggests a large safety margin in the upper dose threshold. Table 2 describes the acoustic parameters used, maternal and fetal characteristics (thickness of the abdominal wall, placenta and uterine walls), size of placental lesions and observed complications for each exposure. HIFU lesions were identified with ultrasound using the imaging probe integrated in the HIFU device at a frequency of 12 MHz. Lesions were visible as hyperechoic regions (Figure 3 ). One HIFU lesion was created in the posterior placenta and five were created in the anterior placenta. All six lesions were identified on ultrasound. The average diameter and depth of the HIFU lesions on ultrasound were 7.7 ± 0.5 mm and 4.8 ± 1.0 mm, respectively. The dimensions measured by ultrasound were similar to those from gross pathology, with a correlation coefficient (r) of 0.91 (P < 0.05) for diameter and 0.89 (P < 0.05) for depth.
Histological examination demonstrated coagulative necrosis within the core of the lesion (Figure 4) . Terminal villi were split with trophoblast desquamation, mesenchymal involution and fibrinoid deposits containing fragmented red blood cells. Congestion and hemorrhagic villitis were seen at the border of the lesion. No damage was seen in the chorionic vessel walls or endothelial cells. There was no inflammation.
DISCUSSION
This study demonstrates, in a monkey model of pregnancy, the feasibility of HIFU exposure in the placenta as a potential tool for the treatment of TTTS. In the female cynomolgus monkey, several anatomical and physiological characteristics during gestation are highly similar to those in human pregnancy, making the pregnant cynomolgus monkey a good model for fetal therapy assessment. In particular, the uterus and placenta share the same shape and structure when compared with humans. Another study has assessed the potential effect of HIFU treatment for TTTS using a sheep model 14 . The sheep model provided organs with comparable volume to those in humans but was unable to demonstrate the ability of HIFU to accurately target placental tissues non-invasively. This preclinical study in monkeys is the first to assess the application of non-invasive HIFU in placental disease with a clinical perspective.
Five HIFU lesions were created in the anterior placenta and one was created in the posterior placenta. The possibility of performing a truly non-invasive treatment using HIFU is of major importance because all other techniques remain invasive and expose pregnant women to several complications [15] [16] [17] . Treatment of a posterior placenta using HIFU exposes the fetus to some complications. Currently, HIFU treatment should be used only for an anterior placenta, whereas fetoscopy appears easier and safer for a posterior placenta 18 . Unlike during HIFU treatment, laser protocols allow for emergency amniotic drainage, however, this could be carried out after a HIFU procedure by the normal technique. The placental lesions were created extracorporeally under ultrasound guidance in only 20 s. These lesions were confirmed by histological analysis and were highly reproducible. The thickness of the placenta in a pregnant monkey is only a few (4-7) millimeters and the technique requires precise focusing. The device described in this study allows for the precise focus of an ultrasound beam to create well-defined lesions in the placenta without treating the entire thickness of the organ. The brevity of the HIFU treatment limits the effect of maternal breathing and fetal movement. Unlike spherical transducers, the toroidal transducer offers the possibility of creating large lesions in a short time, as well as of occluding blood vessels up to 5 mm in diameter 19, 20 . It is expected that HIFU will be able to coagulate vessels and not induce ruptures, but this needs to be further investigated. Previous studies using a similar HIFU device demonstrated that HIFU can occlude vessels of less than 6 mm in diameter and does not rupture vessels and anastomoses 20 . Dichorionization has been proposed for the treatment of TTTS and could reduce the recurrence of TTTS and iatrogenic twin anemia-polycythemia sequence [21] [22] [23] . Unlike fetoscopy, coagulation using HIFU for treatment of TTTS depends on the depth of the placenta. Because the arteriovenous anastomoses communicate at depth, HIFU may have the potential to replicate the selective vascular blood occlusion achieved by laser, while preserving vital anastomoses 24, 25 . Selective coagulation of placental vessels using an ultrasound-guided HIFU device is theoretically possible, however, at present, color Doppler has not been considered efficient enough for immediate application 26 . On the other hand, locating the virtual equator by ultrasound remains difficult, which would limit the possibility of performing dichorionization by HIFU. Clinically, creating serial HIFU lesions along the placental equator for dichorionization could perhaps be facilitated by the use of a three-dimensional ultrasound imaging probe incorporated into the clinical HIFU device. The effect of a large placental coagulation on fetal hemodynamic balance and on the intertwin vascular distribution needs to be established clinically by long-term studies. In our opinion, in order to limit adverse fetal effects, coagulation should not exceed 20% of the placental volume.
To find the best compromise between the creation of a placental lesion and preservation of intervening tissue, the acoustic power and time of exposure were increased gradually. In our numerical and in-vitro optimization studies, ultrasound exposure intensities higher than the ones used in this study produced uncontrolled mechanical effects, and maximum thresholds were applied, leading to the optimized protocol presented here. These safeguards mean that the single incidence of uterine and fetal skin burns observed in this study was associated with repeat exposure at the same location, resulting in overexposure of this region and subsequent thermal build-up. Despite this limitation, there was no maternal, uterine or fetal damage or damage to adjacent tissue when using the appropriate parameters. The treatment protocol used in this study was not designed to observe ablations in the long term. Cesarean sections were performed immediately after HIFU treatment. Monitoring of lesions induced by HIFU will be investigated in further studies to assess the effects of HIFU on the placenta several weeks after treatment.
Other potential difficulties still remain to be addressed before HIFU can be implemented for human treatment. The thickness of the abdominal wall of this animal model (4.4-13.5 mm) is far less than that of a human. Nevertheless, the toroidal transducer used in this study is able to create lesions at 70 mm from the transducer and seems to be adequate for clinical practice. In addition, the possibility of inducing placental lesions non-invasively for the treatment of placenta accreta has been demonstrated recently 27 . This study demonstrates that the thickness of the intervening tissues is not a limiting factor for HIFU therapy. Treatment depth can be adjusted. HIFU treatments are guided by either magnetic resonance imaging or ultrasound 28 . For this preclinical work, temperatures of the skin and amniotic cavity were verified using thermocouples. Guidance by ultrasound is sufficient to target accurately the region to be treated and evaluate the resulting coagulation 29 . Temperature estimation during treatment will not be used clinically; it is not an absolute requirement if targeting is accurate.
In conclusion, the data collected to investigate the safety and potential of ultrasound-guided HIFU treatment showed the possibility of inducing well-defined and controlled placental lesions without complications to fetal or maternal tissues. Despite the need to confirm the feasibility of HIFU for dichorionization and to observe maternal and fetal outcomes over a longer period, these initial feasibility studies demonstrate the utility of ultrasound-guided HIFU to target and selectively ablate placental tissue. This raises the prospect of non-invasive HIFU treatment of TTTS and other related conditions resulting from pathological placentae in human pregnancy.
